Please use this identifier to cite or link to this item: https://idr.l1.nitk.ac.in/jspui/handle/123456789/11005
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThomas, K.D.-
dc.contributor.authorAdhikari, A.V.-
dc.contributor.authorChowdhury, I.H.-
dc.contributor.authorSandeep, T.-
dc.contributor.authorMahmood, R.-
dc.contributor.authorBhattacharya, B.-
dc.contributor.authorSumesh, E.-
dc.date.accessioned2020-03-31T08:23:35Z-
dc.date.available2020-03-31T08:23:35Z-
dc.date.issued2011-
dc.identifier.citationEuropean Journal of Medicinal Chemistry, 2011, Vol.46, 10, pp.4834-4845en_US
dc.identifier.urihttp://idr.nitk.ac.in/jspui/handle/123456789/11005-
dc.description.abstractNew series of quinoline-oxazolidinone hybrid molecules were synthesized based on the preliminary docking studies. All the newly synthesized compounds were characterized by spectral analyses. The newly synthesized compounds were screened for their antimycobacterial properties based on the promising preliminary antibacterial screening results. Amongst tested compounds, compounds 8a, 8j and 13a were active at 0.65 ?g/mL against Mycobacterium tuberculosis H 37Rv strain. The mode of action of these active compounds was carried out by docking of receptor enoyl-ACP reductase with newly synthesized candidate ligands 8a, 8j and 13a. These compounds exhibited well established bonds with one or more amino acids in the receptor active pocket. From the docking studies, compound 8j was considered to be the best inhibitor. 2011 Elsevier Masson SAS. All rights reserved.en_US
dc.titleDesign, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular propertiesen_US
dc.typeArticleen_US
Appears in Collections:1. Journal Articles

Files in This Item:
File Description SizeFormat 
11005.pdf887.31 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.